'JN.1 Variant Not Fatal But...': Ex-AIIMS Chief Randeep Guleria On Rising Covid-19 Cases
Dr Guleria said COVID-19 vaccines protect against the JN.1 variant, though not fully due to its mutations. They still lower the risk of severe illness, hospitalisation and death
Several countries, including India, are witnessing a fresh surge in COVID-19 cases, sparking renewed public concern. After a period of relative decline, infections are once again on the rise—driven by emerging variants.
Amid this uptick, Dr. Randeep Guleria, former director of AIIMS Delhi, has weighed in on the situation, offering insights and advice on how to stay safe. Speaking to a private news channel, Dr. Guleria explained that the increase in COVID-19 cases is primarily due to the JN.1 variant, first identified in August 2023.
This variant, a sub-variant of the Omicron lineage, is spreading rapidly due to mutations in the spike protein, enabling it to evade the immune system. Dr. Guleria shared that while the JN.1 variant is not highly fatal and generally causes mild symptoms such as fever, cough, sore throat, cold, and runny nose, it can be more dangerous for the elderly, individuals with comorbidities like diabetes or heart disease, and those with weakened immune systems. Dr. Guleria emphasised that these vulnerable groups should adhere strictly to COVID-19 protocols to avoid infection.
The situation in India remains under control, but ongoing surveillance of the new variant is necessary, he said adding that preparations should be made to handle any potential escalation.
The former AIIMS director said current data suggests that COVID-19 vaccines offer protection against the JN.1 variant, although they may not fully prevent infection due to its mutations. Vaccines help reduce the severity of the illness and the risk of hospitalisation or death. However, the constant mutations in the virus may decrease the effectiveness of older vaccines, he cautioned.
According to experts, people with serious health conditions should take extra precautions to avoid COVID-19. In addition to vaccines, various antiviral medications are now available, which can help treat COVID-19 and reduce the severity of symptoms, they said.
These drugs have proven effective against the virus and have contributed to lower mortality rates compared to the early stages of the pandemic, they said adding that antiviral medications are particularly beneficial for high-risk patients, aiding in their recovery.
Experts have advised that since COVID-19 symptoms often resemble those of other infections, anyone experiencing a cough, cold, or fever should consider getting tested.
First Published:
May 28, 2025, 15:03 IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
34 minutes ago
- New Indian Express
Beyond the Burn: The Silent Strain of Over-Exercising on the Heart
Gyms are crowded, marathon sign-ups are rising, and fitness has become a lifestyle badge these days, but doctors caution that overburdening the body — whether through excessive cardio, heavy lifting, or even long-distance running — can increase the risk of exercise-induced heart problems. 'Heart attacks, once considered a problem mainly for those above 60, are now increasingly being reported among younger people, especially after the COVID-19 pandemic,' says Dr Sudhir Kumar, consultant neurologist, Apollo Hospitals, Jubilee Hills. He adds, 'What many don't realise is that the heart actually sends out warning signals nearly 12 years in advance. Unfortunately, these symptoms are often dismissed as normal ageing or fatigue.' For earlier generations, daily life itself was exercise — walking long distances, cycling, hand-washing clothes, grinding grains, and living in joint families, an experience that made for less stress. As a result, heart problems were rare and appeared only later in life. Today, sedentary desk jobs, poor sleep, junk food, and high stress levels are silently pumping heart diseases into younger age groups.
Time of India
2 hours ago
- Time of India
Columbia scientists develop world's first prototype ‘Universal Antiviral'
Scientists at Columbia University are developing a universal antiviral. This treatment aims to protect against many viruses, including influenza and COVID-19. The therapy is inspired by a rare genetic mutation. It uses mRNA technology to produce antiviral proteins. Tests on mice and hamsters show reduced viral replication. This offers short-term protection during outbreaks. Tired of too many ads? Remove Ads Rare disorder reveals hidden defense Tired of too many ads? Remove Ads Turning biology into therapy A temporary but powerful shield Challenges ahead A team of Columbia University scientists says it may be closer than ever to creating a universal antiviral , a treatment designed to temporarily shield people against a wide range of viruses, from influenza to experimental therapy, detailed August 13 in Science Translational Medicine , is inspired by a rare genetic mutation that gives a small number of people an extraordinary ability: resistance to nearly all viral infections About 15 years ago, Columbia immunologist Dr. Dusan Bogunovic began studying patients with a rare immune condition known as ISG15 deficiency . Though these individuals were more prone to certain bacterial infections, they seemed to shrug off viral illnesses without ever developing study revealed that the mutation caused a constant, low-level state of immune activation, a kind of background inflammation that was highly effective at blocking viruses. 'The type of inflammation they had was antiviral,' Bogunovic recalled in a Columbia University of reproducing the harmful aspects of ISG15 deficiency, Bogunovic's team identified 10 specific proteins responsible for most of the antiviral protection. They then engineered an mRNA-based therapy, similar in design to COVID-19 vaccines, that prompts cells to briefly produce those through the nose into the lungs of mice and hamsters, the treatment significantly reduced replication of both influenza and SARS-CoV-2, the virus that causes COVID-19. In cell culture tests, the therapy appeared to resist a wide variety of a vaccine, which builds lasting immunity to a specific pathogen, this treatment provides only short-term protection, estimated at three to four days in animals. Researchers say that could make it particularly valuable at the beginning of outbreaks, giving first responders, health workers, and high-risk populations an immediate layer of defense while vaccines are still in therapy also does not interfere with long-term immunity, meaning patients could still develop protective memory after infection or concept remains in early stages. Researchers say improving the delivery system, ensuring enough of the proteins are produced in the right tissues, is the biggest hurdle before moving into human trials. More work is also needed to determine how long protection lasts and how safe repeated dosing might experts say the findings are promising. By activating the body's own antiviral machinery, the therapy could offer a virus-agnostic defense that works even when the identity of a new pathogen is unknown.
Time of India
3 hours ago
- Time of India
Couple gets 2nd chance at having baby as HC gives IVF nod to overage husband
1 2 Kolkata: A couple from Narendrapur received a second chance at having a child through IVF after the Calcutta High Court on Monday allowed the man, now 59 years old, through the process despite him overshooting the age criteria by four years. Justice Amrita Sinha directed an IVF clinic to permit the couple to undergo the procedures for IVF. The Assisted Reproductive Technology (Regulation) 2021, implemented in 2022, states the service is available to women above 21 years and below 50 and to men above 21 and below 55. You Can Also Check: Kolkata AQI | Weather in Kolkata | Bank Holidays in Kolkata | Public Holidays in Kolkata | Gold Rates Today in Kolkata | Silver Rates Today in Kolkata The Narendrapur couple married in 2017. After their failed attempts at having a baby, doctors recommended IVF. The couple approached an IVF clinic in 2019, when the man was aged 53, well within the age limit. But their procedure was halted abruptly in March 2020 as the Covid struck. After the pandemic ended, the couple again visited the IVF centre in 2023. Doctors found that though the woman, 45 at that time, was within the age limit, the husband had reached 57. Turned away, the couple approached the Calcutta High Court, seeking permission to go for IVF. The HC had recently granted permission for IVF to several couples, among whom one of the spouses had slightly overshot the age limit. The Narendrapur couple's counsel, Debangan Bhattacharjee, relied on a judgment by Justice Sinha in a case, in which the husband had also crossed the age bar. In that case, the childless couple, married for 30 years, desired to go in for IVF, but the husband was 58 years old. In that case, Justice Sinha had observed that it would be "sheer injustice" to the woman if she was not allowed to avail of ARTS as her husband was ineligible. "For the ineligibility of the man, the wife ought not suffer," Justice Sinha had observed. Pointing out that the law was enforced in 2022, the Narendrapur couple, in their petition, had raised a question on "what happened to people who had started the fertility procedure before the Act came into being, and suddenly found themselves disqualified during the course of their treatment after the Act was enforced". Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
